Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 302

1.

Mercury isotope signatures of digests and sequential extracts from industrially contaminated soils and sediments.

Grigg ARC, Kretzschmar R, Gilli RS, Wiederhold JG.

Sci Total Environ. 2018 Sep 15;636:1344-1354. doi: 10.1016/j.scitotenv.2018.04.261. Epub 2018 May 5.

PMID:
29913595
2.

Strategies to enhance the graft versus tumour effect after allogeneic haematopoietic stem cell transplantation.

Wong E, Davis JE, Grigg A, Szer J, Ritchie D.

Bone Marrow Transplant. 2018 Jun 14. doi: 10.1038/s41409-018-0244-z. [Epub ahead of print]

PMID:
29904127
3.

Management of Pregnancy in Women With Chronic Myeloid Leukemia.

Ross DM, Burbury KL, Grigg AP, Hughes TP, Seymour JF.

J Clin Oncol. 2018 May 31:JCO2018786137. doi: 10.1200/JCO.2018.78.6137. [Epub ahead of print] No abstract available.

PMID:
29851544
4.

Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabine.

Prabahran A, Tacey M, Fleming S, Wei A, Tate C, Marlton P, Wight J, Grigg A, Tuckfield A, Szer J, Ritchie D, Chee L.

Eur J Haematol. 2018 May 2. doi: 10.1111/ejh.13089. [Epub ahead of print]

PMID:
29719925
5.

Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI.

Wight JC, Chong G, Grigg AP, Hawkes EA.

Blood Rev. 2018 Mar 26. pii: S0268-960X(17)30159-5. doi: 10.1016/j.blre.2018.03.005. [Epub ahead of print] Review.

PMID:
29605154
6.

Bi-Allelic Mutations in STXBP2 Reveal a Complementary Role for STXBP1 in Cytotoxic Lymphocyte Killing.

Lopez JA, Noori T, Minson A, Li Jovanoska L, Thia K, Hildebrand MS, Akhlaghi H, Darcy PK, Kershaw MH, Brown NJ, Grigg A, Trapani JA, Voskoboinik I.

Front Immunol. 2018 Mar 15;9:529. doi: 10.3389/fimmu.2018.00529. eCollection 2018.

7.

An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma.

Wight JC, Hawkes EA, Berlangieri SU, Khor R, Grigg AP.

Leuk Lymphoma. 2018 Mar 23:1-3. doi: 10.1080/10428194.2018.1452217. [Epub ahead of print] No abstract available.

PMID:
29569979
8.

Echocardiography has low utility in cancer patients with Staphylococcus aureus bacteraemia: findings from a retrospective study.

Loh Z, Estacio O, Grigg A, Holmes NE, Chong G, Hawkes EA.

Support Care Cancer. 2018 Mar 21. doi: 10.1007/s00520-018-4162-9. [Epub ahead of print]

PMID:
29564624
9.

Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD.

Minson A, Douglas G, Bilmon I, Grigg A.

Br J Haematol. 2018 Mar 13. doi: 10.1111/bjh.15186. [Epub ahead of print] No abstract available.

PMID:
29532918
10.

Peripheral blood stem cell mobilisation with G-CSF alone versus G-CSF and cyclophosphamide after bortezomib, cyclophosphamide and dexamethasone induction in multiple myeloma.

Chua CC, Lim HY, Chai KL, Ong J, Sim S, Wood C, Dickinson M, Campbell P, Hempton J, King H, Dowsing C, Bergin K, Muir S, Gibbs S, Grigg A.

Bone Marrow Transplant. 2018 Mar 9. doi: 10.1038/s41409-018-0152-2. [Epub ahead of print]

PMID:
29523889
11.

The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.

Fox LC, Cummins KD, Costello B, Yeung D, Cleary R, Forsyth C, Tatarczuch M, Burbury K, Motorna O, Shortt J, Fleming S, McQuillan A, Schwarer A, Harrup R, Holmes A, Ratnasingam S, Chan KL, Hsu WH, Ashraf A, Putt F, Grigg A.

Blood Adv. 2017 May 15;1(13):802-811. doi: 10.1182/bloodadvances.2016003889. eCollection 2017 May 23.

12.

Limited utility of routine chest X-ray in initial evaluation of neutropenic fever in patients with haematological diseases undergoing chemotherapy.

Estacio O, Loh Z, Baker A, Chong G, Grigg A, Churilov L, Hawkes EA.

Intern Med J. 2018 May;48(5):556-560. doi: 10.1111/imj.13712.

PMID:
29227565
13.

Allogeneic stem cell transplantation as a risk factor for recurrent melanoma.

Stevens H, Raj K, Ashby M, Grigg A.

Leuk Lymphoma. 2018 Jul;59(7):1750-1752. doi: 10.1080/10428194.2017.1393670. Epub 2017 Oct 31. No abstract available.

PMID:
29087220
14.

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.

Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, Heinz WJ, Raad I, Schanz U, Meyer RG, Hammond SP, Mullane KM, Ostermann H, Ullmann AJ, Zimmerli S, Van Iersel MLPS, Hepler DA, Waskin H, Kartsonis NA, Maertens J.

J Antimicrob Chemother. 2017 Dec 1;72(12):3501. doi: 10.1093/jac/dkx382. No abstract available.

PMID:
29029280
15.

Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease.

Cornely OA, Robertson MN, Haider S, Grigg A, Geddes M, Aoun M, Heinz WJ, Raad I, Schanz U, Meyer RG, Hammond SP, Mullane KM, Ostermann H, Ullmann AJ, Zimmerli S, Van Iersel MLPS, Hepler DA, Waskin H, Kartsonis NA, Maertens J.

J Antimicrob Chemother. 2017 Dec 1;72(12):3406-3413. doi: 10.1093/jac/dkx263.

PMID:
28961714
16.

Early radiological intervention and haematology screening is associated with excellent outcomes in Budd-Chiari syndrome.

Mo A, Testro A, French J, Robertson M, Angus P, Grigg A.

Intern Med J. 2017 Dec;47(12):1361-1367. doi: 10.1111/imj.13544.

PMID:
28675622
17.

An individualised risk-adapted protocol of pre- and post transplant zoledronic acid reduces bone loss after allogeneic stem cell transplantation: results of a phase II prospective trial.

Grigg A, Butcher B, Khodr B, Bajel A, Hertzberg M, Patil S, D'Souza AB, Ganly P, Ebeling P, Wong E.

Bone Marrow Transplant. 2017 Sep;52(9):1288-1293. doi: 10.1038/bmt.2017.108. Epub 2017 Jun 19.

PMID:
28628088
18.

Assessment of Behavioral Disruption in Rats with Abdominal Inflammation Using Visual Cue Titration and the Five-choice Serial-reaction Time Task.

Martin TJ, Strassburg TJ, Grigg AL, Kim SA, Ririe DG, Eisenach JC.

Anesthesiology. 2017 Aug;127(2):372-381. doi: 10.1097/ALN.0000000000001702.

PMID:
28542002
19.

Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.

Bradstock KF, Link E, Di Iulio J, Szer J, Marlton P, Wei AH, Enno A, Schwarer A, Lewis ID, D'Rozario J, Coyle L, Cull G, Campbell P, Leahy MF, Hahn U, Cannell P, Tiley C, Lowenthal RM, Moore J, Cartwright K, Cunningham I, Taper J, Grigg A, Roberts AW, Benson W, Hertzberg M, Deveridge S, Rowlings P, Mills AK, Gill D, Bardy P, Campbell L, Seymour JF; Australasian Leukaemia & Lymphoma Group.

J Clin Oncol. 2017 May 20;35(15):1678-1685. doi: 10.1200/JCO.2016.70.6374. Epub 2017 Apr 3.

PMID:
28368672
20.

Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.

Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A, Gill D, Ho SJ, Cull G, Fay K, Chong G, Grigg A, Lewis ID, Milliken S, Renwick W, Hahn U, Filshie R, Kannourakis G, Watson AM, Warburton P, Wirth A, Seymour JF, Hofman MS, Hicks RJ; Australasian Leukaemia Lymphoma Group (ALLG).

Haematologica. 2017 Feb;102(2):356-363. doi: 10.3324/haematol.2016.154039. Epub 2016 Nov 10.

21.

Is Upfront Escalated BEACOPP for Advanced Hodgkin Lymphoma Becoming a Distant Memory?

Hawkes EA, Chong G, Grigg A.

J Clin Oncol. 2017 Jan 20;35(3):371-372. doi: 10.1200/JCO.2016.68.2047. Epub 2016 Oct 28. No abstract available.

PMID:
28095269
22.

Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).

Rummel M, Kim TM, Aversa F, Brugger W, Capochiani E, Plenteda C, Re F, Trask P, Osborne S, Smith R, Grigg A.

Ann Oncol. 2017 Apr 1;28(4):836-842. doi: 10.1093/annonc/mdw685.

PMID:
28031173
23.

Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.

Grigg A, Dyer MJ, Díaz MG, Dreyling M, Rule S, Lei G, Knapp A, Wassner-Fritsch E, Marlton P.

Haematologica. 2017 Apr;102(4):765-772. doi: 10.3324/haematol.2016.152272. Epub 2016 Dec 23.

24.

Use of computed tomography abdomen and pelvis for investigation of febrile neutropenia in adult haematology patients.

Lim HY, Ashby M, Williams B, Grigg A.

Intern Med J. 2016 Nov;46(11):1332-1336. doi: 10.1111/imj.13235.

PMID:
27813352
25.

Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).

Ho PJ, Tay L, Teo J, Marlton P, Grigg A, St Pierre T, Brown G, Badcock CA, Traficante R, Gervasio OL, Bowden DK.

Eur J Haematol. 2017 Feb;98(2):97-105. doi: 10.1111/ejh.12793. Epub 2016 Sep 20.

PMID:
27537786
26.

Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.

Jeong W, Haywood P, Shanmuganathan N, Lindsay J, Urbancic K, Ananda-Rajah MR, Chen SC, Bajel A, Ritchie D, Grigg A, Seymour JF, Peleg AY, Kong DC, Slavin MA.

J Antimicrob Chemother. 2016 Dec;71(12):3540-3547. Epub 2016 Aug 11.

PMID:
27521358
27.

The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state.

Alhawiti N, Burbury KL, Kwa FA, O'Malley CJ, Shuttleworth P, Alzard M, Hamadi A, Grigg AP, Jackson DE.

Thromb Res. 2016 Sep;145:54-64. doi: 10.1016/j.thromres.2016.07.019. Epub 2016 Jul 30.

PMID:
27494773
28.

Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.

Douglas G, Harrison C, Forsyth C, Bennett M, Stevenson W, Hounsell J, Ratnasingam S, Ritchie D, Ross DM, Grigg A.

Leuk Lymphoma. 2017 Jan;58(1):89-95. Epub 2016 Jul 25.

PMID:
27454522
29.

Fanconi anemia in 55-year-old identical twins first presenting as fatal post-chemotherapy pancytopenia.

Stevens H, Chyn Chua C, Wallis M, Hew S, Grigg A.

Am J Hematol. 2016 Dec;91(12):1273-1276. doi: 10.1002/ajh.24488. Epub 2016 Aug 8. No abstract available.

30.

The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.

Eadie LN, Dang P, Saunders VA, Yeung DT, Osborn MP, Grigg AP, Hughes TP, White DL.

Leukemia. 2017 Jan;31(1):75-82. doi: 10.1038/leu.2016.179. Epub 2016 Jun 24.

PMID:
27416909
31.
32.

Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.

Jalali A, Ha FJ, Chong G, Grigg A, Mckendrick J, Schwarer AP, Doig R, Hamid A, Hawkes EA.

Ann Hematol. 2016 Apr;95(5):809-16. doi: 10.1007/s00277-016-2611-4. Epub 2016 Feb 15.

PMID:
26878861
33.

Characterizing Key Components of a Medical Home Among Rural Adolescents.

Dixon SK, Hoopes AJ, Benkeser D, Grigg A, Grow HM.

J Adolesc Health. 2016 Feb;58(2):141-7. doi: 10.1016/j.jadohealth.2015.10.249.

PMID:
26802989
34.

Fertility in premenopausal women post autologous stem cell transplant with BEAM conditioning.

Lasica M, Taylor E, Bhattacharyya P, Bennett A, Cooke RE, Stern C, Agresta F, Ayton R, Grigg A.

Eur J Haematol. 2016 Oct;97(4):348-52. doi: 10.1111/ejh.12737. Epub 2016 Feb 23.

PMID:
26773518
35.

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.

Iland HJ, Collins M, Bradstock K, Supple SG, Catalano A, Hertzberg M, Browett P, Grigg A, Firkin F, Campbell LJ, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF; Australasian Leukaemia and Lymphoma Group.

Lancet Haematol. 2015 Sep;2(9):e357-66. doi: 10.1016/S2352-3026(15)00115-5. Epub 2015 Aug 20.

PMID:
26685769
36.

Do state-and-transition models derived from vegetation succession also represent avian succession in restored mine pits?

Craig MD, Stokes VL, Fontaine JB, Hardy GE, Grigg AH, Hobbs RJ.

Ecol Appl. 2015 Oct;25(7):1790-806.

PMID:
26591446
37.

Prefmab: Final Analysis Of Patient Satisfaction With Subcutaneous Versus Intravenous Rituximab In Previously Untreated Cd20+ Diffuse Large B-Cell Lymphoma Or Follicular Lymphoma.

Rummel M, Kim TM, Plenteda C, Capochiani E, Mendoza M, Smith R, Osborne S, Grigg A.

Value Health. 2015 Nov;18(7):A469. doi: 10.1016/j.jval.2015.09.1237. Epub 2015 Oct 20. No abstract available.

38.

Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multicentre audit.

Doan TN, Kirkpatrick CM, Walker P, Slavin MA, Ananda-Rajah MR, Morrissey CO, Urbancic KF, Grigg A, Spencer A, Szer J, Seymour JF, Kong DC.

J Antimicrob Chemother. 2016 Feb;71(2):497-505. doi: 10.1093/jac/dkv343. Epub 2015 Oct 30.

PMID:
26518050
39.

Cellular Mechanisms Underlying Complete Hematological Response of Chronic Myeloid Leukemia to BRAF and MEK1/2 Inhibition in a Patient with Concomitant Metastatic Melanoma.

Andrews MC, Turner N, Boyd J, Roberts AW, Grigg AP, Behren A, Cebon J.

Clin Cancer Res. 2015 Dec 1;21(23):5222-34. doi: 10.1158/1078-0432.CCR-15-0393. Epub 2015 Jul 22.

40.

Novel fibrinogen mutations (Aα17Gly→Cys and Aα381Ser→Phe) occurring with a 312Thr→Ala polymorphism: allelic phase assigned by direct mass measurement.

Brennan SO, Laurie AD, Mo A, Grigg A.

Blood Coagul Fibrinolysis. 2015 Dec;26(8):882-6. doi: 10.1097/MBC.0000000000000316.

PMID:
26083984
41.

Programmed cell death-1 inhibition in lymphoma.

Hawkes EA, Grigg A, Chong G.

Lancet Oncol. 2015 May;16(5):e234-45. doi: 10.1016/S1470-2045(15)70103-8. Review.

PMID:
25943068
42.

Diagnostic medical radiation exposure in surveillance of aggressive lymphoma: clinical trial design should reflect clinical practice.

Hawkes EA, Chong G, Grigg A.

J Clin Oncol. 2015 Apr 1;33(10):1219-20. doi: 10.1200/JCO.2014.60.0486. Epub 2015 Feb 17. No abstract available.

PMID:
25691672
43.

Effects of the dopamine/norepinephrine releaser phenmetrazine on cocaine self-administration and cocaine-primed reinstatement in rats.

Czoty PW, Tran P, Thomas LN, Martin TJ, Grigg A, Blough BE, Beveridge TJ.

Psychopharmacology (Berl). 2015 Jul;232(13):2405-14. doi: 10.1007/s00213-015-3875-4. Epub 2015 Feb 13.

44.

Assessment of attention threshold in rats by titration of visual cue duration during the five choice serial reaction time task.

Martin TJ, Grigg A, Kim SA, Ririe DG, Eisenach JC.

J Neurosci Methods. 2015 Feb 15;241:37-43. doi: 10.1016/j.jneumeth.2014.12.007. Epub 2014 Dec 18.

45.

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.

Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP; Australasian Leukaemia and Lymphoma Group.

Blood. 2015 Feb 5;125(6):915-23. doi: 10.1182/blood-2014-07-590315. Epub 2014 Dec 17.

46.

Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014.

Morrissey CO, Gilroy NM, Macesic N, Walker P, Ananda-Rajah M, May M, Heath CH, Grigg A, Bardy PG, Kwan J, Kirsa SW, Slavin M, Gottlieb T, Chen S.

Intern Med J. 2014 Dec;44(12b):1298-314. doi: 10.1111/imj.12596. Review.

PMID:
25482742
47.

Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.

Fleming S, Yannakou CK, Haeusler GM, Clark J, Grigg A, Heath CH, Bajel A, van Hal SJ, Chen SC, Milliken ST, Morrissey CO, Tam CS, Szer J, Weinkove R, Slavin MA.

Intern Med J. 2014 Dec;44(12b):1283-97. doi: 10.1111/imj.12595. Review.

PMID:
25482741
48.

Vanishing bile duct syndrome and immunodeficiency preceding the diagnosis of Hodgkin lymphoma.

Yeh P, Lokan J, Anantharajah A, Grigg A.

Intern Med J. 2014 Dec;44(12a):1240-4. doi: 10.1111/imj.12609.

PMID:
25442758
49.

Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies.

Teh BW, Teng JC, Urbancic K, Grigg A, Harrison SJ, Worth LJ, Slavin MA, Thursky KA.

Haematologica. 2015 Jan;100(1):e28-31. doi: 10.3324/haematol.2014.114025. Epub 2014 Oct 10. No abstract available.

50.

The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia.

Banerjee A, Mifsud NA, Bird R, Forsyth C, Szer J, Tam C, Kellner S, Grigg A, Motum P, Bentley M, Opat S, Grigoriadis G.

Br J Haematol. 2015 Feb;168(4):576-82. doi: 10.1111/bjh.13151. Epub 2014 Oct 1.

PMID:
25271366

Supplemental Content

Support Center